Treprostinil Palmitil not checked

Insmed Incorporated · INS1009

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
6 active
11 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral inhalation using a capsule-based dry powder inhaler device.”In the company’s words, NCT07481981 on ClinicalTrials.gov
Tested for
Interstitial Lung Disease (3 trials), Pulmonary Arterial Hypertension (2 trials), Pulmonary Hypertension (2 trials), Progressive Pulmonary Fibrosis, Hepatic Impairment
Main trialPhase 3
“The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.”In the company’s words, NCT07481981 on ClinicalTrials.gov
Other names
INS1009

Other drugs for Interstitial Lung Disease

All 71 drugs for Interstitial Lung Disease

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 28 Dec 2028 A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Phase 3Recruiting 30 Dec 2028 Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 3Recruiting 31 Aug 2030 A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
Phase 3Recruiting 22 Jan 2031 An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 2/3Active, not recruiting 31 Dec 2026 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Phase 1Recruiting 7 Feb 2027 A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Phase 2/3Completed 1 Apr 2026 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 2Terminated 26 Aug 2022 A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
Phase 2Completed 14 Mar 2024 A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Phase 2Completed 27 Mar 2025 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Phase 1Completed 12 Jan 2021 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Treprostinil Palmitil

Following is part of Solo: you see every change to Treprostinil Palmitil the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in